The typical case for the fund is to invest in rounds with 4-5 participants. Despite the BoxOne Ventures, startups are often financed by TandemLaunch. The meaningful sponsors for the fund in investment in the same round are White Star Capital, Richard Reiner, Panache Ventures.
Among the various public portfolio startups of the fund, we may underline dfuse Among the most successful fund investment fields, there are Blockchain, Software. Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund.
The fund is generally included in 2-6 deals every year. Deals in the range of 1 - 5 millions dollars are the general things for fund. The high activity for fund was in 2019.
The overall number of key employees were 1.
|9M||07 Dec 2020||Canada, Kitchener|
|3M||11 Oct 2020|
|4M||17 Sep 2020||Singapore, Singapore|
|15 Jul 2020||Canada, Edmonton|
Floating Point Group
|2M||28 May 2020||United States, Summit|
|16 Dec 2019||Canada, Quebec City|
ORA Graphene Audio Inc.
|795K||10 Oct 2019||Canada, Montréal|
|2M||16 Sep 2019||United States, Berkeley|
|3M||26 Jun 2019||Canada, Montreal|
– Revelio Labs announced its seed capital raise of $4.0m. – The round was led by Barclays and K20 Fund, with additional funding from NYU Ventures, BDMI, BoxOne Ventures, DataFrame Ventures, 840 Venture Partners and industry veterans, including Michael Recce and Jeremy Baksht, and values Revelio Labs at a $29m. – The capital will be used to expand Revelio Labs’ offering beyond investment management, to corporate HR and strategy. Read more
– AXONIS secured an additional $5m in funding. – The round was led by Alexandria Venture Investments with participation by R3 Bio, BoxOne Ventures and Civilization Ventures and two leading spinal cord injury non-profit foundations, the Christopher & Dana Reeve Foundation and Spinal Research. – The new investment will support AXONIS’ next development phase as it continues to advance its novel neuromodulating technology into the clinic. – The Company’s pipeline includes neuron-reviving therapeutics that... Read more
By posting comments on our website you confirm and acknowledge that:
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.